Literature DB >> 1880573

Rest-injected thallium-201 imaging for assessing viability of severe asynergic regions.

T Mori1, K Minamiji, H Kurogane, K Ogawa, Y Yoshida.   

Abstract

To evaluate the utility of rest-injected 201Tl initial and delayed images for assessing the viability of severe asynergic regions, we studied 17 patients with apparently prior infarcted myocardium in combination with 99mTc ventriculography before and after revascularization. In 51 regions with severe asynergy, the percent 201Tl uptake was calculated as the ratio of counts on the segment with asynergy to the maximum counts on the normal segment. Eleven of 14 regions with resting 201Tl redistribution (Group 1) had improved wall motion after revascularization. However, 14 of 37 regions without redistribution also improved (Group 2). Twenty-three regions without redistribution or improved wall motion after revascularization (Group 3) had lower regional 201Tl uptake on their delayed images than those in Groups 1 and 2. Moreover, the initial regional uptake of Group 2 was higher than that of Group 3. These results suggest that redistribution on rest-injected 201Tl scans indicates reversibility of severely asynergic myocardium and that high 201Tl uptake in regions without redistribution may predict improvement in wall motion after revascularization. We conclude that 201Tl uptake may be useful as a marker of viability of severe asynergic regions before revascularization.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1880573

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  29 in total

1.  Absolute value of the difference of Tl-201 uptake between redistribution and rest is a specific marker of myocardial viability.

Authors:  M Dziuk; D Borkowski; W Kwiatkowski; A Cwetsch; M Cholewa
Journal:  Int J Card Imaging       Date:  2000-04

2.  Viable myocardium and reinjection of thallium.

Authors:  S R Underwood; D J Pennell
Journal:  Br Heart J       Date:  1992-12

3.  Evaluation of myocardial viability by myocardial perfusion imaging: should nitrates be used?

Authors:  Z X He; M S Verani
Journal:  J Nucl Cardiol       Date:  1998 Sep-Oct       Impact factor: 5.952

4.  Comparative accuracy of various Tl-201 reinjection imaging protocols to detect myocardial viability.

Authors:  H Naruse; T Kondo; T Arii; M Morita; M Ohyanagi; T Iwasaki; M Fukuchi
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

5.  Can technetium 99m-labeled sestamibi track myocardial viability?

Authors:  J E Udelson
Journal:  J Nucl Cardiol       Date:  1994 Nov-Dec       Impact factor: 5.952

Review 6.  Choosing a thallium-201 or technetium 99m sestamibi imaging protocol.

Authors:  J E Udelson
Journal:  J Nucl Cardiol       Date:  1994 Sep-Oct       Impact factor: 5.952

7.  Thallium 201 for detection of viable myocardium: comparison of different reinjection protocols.

Authors:  L Favaro; F Masini; W Serra; G Gavaruzzi; G Benecchi; S Tagliavini; G Botti
Journal:  J Nucl Cardiol       Date:  1994 Nov-Dec       Impact factor: 5.952

8.  Resting technetium-99m methoxyisobutylisonitrile cardiac imaging in chronic coronary artery disease: comparison with rest-redistribution thallium-201 scintigraphy.

Authors:  A Cuocolo; S Maurea; L Pace; E Nicolai; A Nappi; M Imbriaco; B Trimarco; M Salvatore
Journal:  Eur J Nucl Med       Date:  1993-12

9.  Dual-isotope myocardial imaging: feasibility, advantages and limitations. Preliminary report on 231 consecutive patients.

Authors:  P Weinmann; J M Foult; D Le Guludec; F Tamgac; D Rechtman; A Neuman; N Caillat-Vigneron; J L Moretti
Journal:  Eur J Nucl Med       Date:  1994-03

10.  Selective intracoronary injection of sestamibi to detect myocardial viability: Prediction of perfusion and contractile recovery after percutaneous transluminal coronary angioplasty.

Authors:  Carlo Trani; Alessandro Giordano; Antonella Lombardo; Alessandro Lupi; Francesca Reale; Roberto Patrizi; Giampiero Patrizi; Mario A Mazzari; Giovanni Schiavoni; Attilio Maseri
Journal:  J Nucl Cardiol       Date:  2003 Sep-Oct       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.